Visiongain Publishes Nebulizer Market Report 2020-2030

24 July 2020
Pharma

Visiongain has launched a new report Nebulizer Market Report 2020-2030: Forecasts by Product (Pneumatic Nebulizer, Ultrasonic Nebulizers, and Mesh Nebulizers), End-user (Hospital & Clinics, Emergency Centres, and Home Healthcare) and by Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). Including Forecasts by Major Developed Countries and Developing Countries, Plus Profiles of Leading Companies.

A nebulizer is an electrically powered device that converts liquid medication into a very fine mist so that it can be breathed directly into the lungs with the help of a face mask or mouthpiece. Nebulizers are usually used in the treatment of asthma, cystic fibrosis, chronic obstructive pulmonary disease (COPD) and other respiratory diseases or disorders. In some cases, a doctor prescribes a nebulizer for a child who has a respiratory infection, such as bronchiolitis. They use oxygen, compressed air or ultrasonic power to break up solutions and suspensions into small aerosol droplets that are inhaled from the mouthpiece of the device. The high growth of nebulizer market is attributed to the rising incidence rate of chronic respiratory diseases, increasing demand for home healthcare devices, and rising geriatric population.

According to the Centers for Disease Control and Prevention (CDC) data, More than 140,000 Americans die of COPD each year. In addition, as per WHO, in 2017, there were around 3.2 million deaths worldwide due to COPD. Rising consumption of alcohol, tobacco, ultra-processed products, including sugar-sweetened beverages is a foremost cause behind the increasing prevalence of respiratory diseases globally. These factors are anticipated to increase the demand for nebulizers driving the market growth.

The preference for treatment in home care settings is growing among patients because of the high-cost burden associated with prolonged hospital stays, particularly for the treatment of chronic diseases. The elder population also prefer treatment under home care settings over hospitals. Technological advances in the healthcare sector is further supporting the adoption of self-diagnosis and treatment devices, such as nebulizers in home care settings driving the growth of the nebulizers market.

The Visiongain report analyst commented “that the current COVID-19 pandemic has led to an enormous surge in demand for nebulizers. There has been an increased use of albuterol inhalers in hospitals for COVID-19 and suspected COVID-19 patients to help with respiratory issues. This is mainly because respiratory viruses are the most common trigger for asthma exacerbations. This is anticipated to drive the market growth during the forecast period.”

According to data from World Population Prospects, by 2050, one in six people in the world will be over age 65 (16%). By 2050, one in four persons living in Europe and Northern America could be aged 65 or over. Elderly people are more vulnerable to respiratory diseases such as COPD and sleep apnea. Therefore, growing geriatric population is expected to expand the patient pool creating an opportunity for the manufacturers in the nebulizers market during the forecast period.

On the other hand, drug loss during nebulization is the major factor off-putting the market growth. However, this can also act as an opportunity for the mesh nebulizer as the devices are manufactured to carry accurate drug dosage thereby reducing the drug loss.

The report covers a detailed competitive outlook that includes market share and company profiles of key players operating in the global market. Key players profiled in the report include Omron Corporation, Koninklijke Philips N.V., PARI Pharma, Allied Healthcare Products, Inc., Becton Dickinson and Company, Agilent Technologies, Medline Industries, Briggs Healthcare, Drive Medical, and GF Health Products, Inc.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Healthcare Cold Chain Logistics Market Report 2020-2030

. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.

16 September 2020

Read

Visiongain Publishes Vaccines Sales Market Report 2020-2030

Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.

14 September 2020

Read

Visiongain Publishes Ophthalmic Ultrasound Systems Market Report 2020-2030

The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.

09 September 2020

Read

Visiongain Publishes Drug Discovery Outsourcing Market Report 2020-2030

The current COVID-19 pandemic is anticipated to have a minor impact on the overall outsourcing business outlook for global drug discovery. Also, significant growth during the COVID-19 pandemic is expected to be seen in the outsourcing of drugs and medicines needed to treat COVID-19 infections.

07 September 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever